

ADULT AMBULATORY INFUSION ORDER 3/2023

Dalbavancin (DALVANCE) Infusion

✓ Insert peripheral IV if no iv access.

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

W eight	: kg	H eight:	cm	Allergies:	D iagnosis Code:						
	ent Start Date			<u> </u>							
	INES FOR OR										
		_	hirth n	nust be on FA	CH page of this order form. This form will be returned if any						
	left blank.				5 pu ₀ 0 0 0						
2		HEET and cor	nnlete	conv of INSUR	ANCE information, Send H&P or most recent chart note						
۷.	2. Send FACE SHEET and complete copy of INSURANCE information. Send H&P or most recent chart must be within the past 12 months.										
3.	Send a copy of related lab results if not available for review in Epic.										
		or related lat	resuit	3 II IIOt availat	ne for review in Epic.						
	nal LABS:										
	CMR Routing overy										
	CMP, Routine, every										
	Sedimentation rate, Routine, every										
	Carlon.										
MEDICA	_	/DALVANCE	برمام ما ۱	turns F0/ 2F0 :	and for the common structure of 1. Free finally in tinfing command						
V		-			ml (or to a concentration of 1 – 5mg/ml), iv, infuse over 30						
	minutes/per protocol. Monitor patients for any infusion-related reactions: Rapid intravenous infusions of										
	dalbavancin (<30 minutes) may cause reactions that resemble "Red-Man Syndrome," (eg, flushing of										
					or slowing the infusion may result in cessation of these						
(-	e with N	NS. Flush with	D5W before and after giving.						
	must select o	ne)									
	500 mg										
	750 mg										
	1,000 mg										
	1,500 mg										
				e blank) If pat	ient has already completed a dose elsewhere, date of when						
-	dose was given here:										
	ONE TIME order. Due for infusion week of										
					Due for first infusion week of						
	Other:										
END OF	TREATMENT	LINE CARE: (must se	elect one)							
	NO, patient	does not hav	e a PICO	C or midline ac	ccess.						
	YES, patient	does have a	PICC or	midline in pla	ce. Please <u>REMOVE</u> line after last dose given.						
	YES, patient does have a PICC or midline in place. Please do NOT remove line after last dose given.										
AS NEE	DED MEDICAT	ΓIONS:									
\checkmark	Dextrose 5%	(D5W) iv bo	us 250	ml, Flush befo	re and after IV medication(s) and as needed with D5W.						
	Alteplase (cathflo activase) injection 2 mg, for clotted or sluggish line.										
	Standard included Nursing Orders:										
		_		ital signs, tole	rance, and presence of infusion-related reactions prior to						
		at the end o									
✓	Central line										

✓ May use/access CVC line and give 500 units (5ml) heparin injection for central line care.



Dalbavancin (DALVANCE) Infusion

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

✓ If hypersensitivity or infusion reactions develop, temporarily hold the infusion, and notify provider immediately. Include hypersensitivity reaction order set. (See attached form).

HYPERSENSITIVITY INFUSION REACTION ORDERS

STOP infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.

- 1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.
 - 2. Maintain IV access with NS line.
 - 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
 - 4. Maintain airway.

<u>SEVERE REACTION</u>: Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

- 1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.
- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated.
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

MEDICATIONS:

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For *MODERATE* Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For *SEVERE* Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.



3/2023 **Dalbavancin (DALVANCE) Infusion** NAME: **INSURANCE:** PROVIDER NAME: **CLINIC NAME and Phone number:**

Patient identification

- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 - 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.

, ,	•	v, I represent the followi	•							
	-	for the care of the patier								
I hold a	n active,	unrestricted license to pr	actice medicine in	Orego	on.					
My phy	sician lic	ense Number is #	nd I an	n acting within my scope of practice and						
authori	zed by la	w to order infusion of the	medications and	blood	products described above for the patient					
	ed on this									
Provider's printed name:										
		nature:								
Date	:									
Please	complete	the following intake qu	estions							
	ty status	the following intake qu	estions.							
	Indepe	ndent								
	Walker									
	Wheelchair									
	Fully de	pendent								
Bariatr	ic needs	•								
	Yes, bri	efly describe		_						
	No									
Transp	ortation	concerns								
	Yes, bri	efly describe								
	No									
Interpr	eter Serv	ice required								
	Yes, lan	guage								
	No									
		sion Services Intake Tean								
Please		e appropriate box for the								
		PORTLAND			Fax- 503-487-3582					
		WILLAMETTE FALLS			Fax- 503-487-3582					
		MEDFORD			Fax- 541-732-3939					
		HOOD RIVER	Phone- 541-387							
		SEASIDE			Fax- 503-470-3146					
		NEWBERG (SSU)	FIIOHE- 303-53	-1450	Fax- 503-537-1449					